Retinopathy

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  Boyd, Shelley R ^a   Advani, Andrew ^a   Altomare, Filiberto ^a   Stockl, Frank ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANDESARTAN; ENALAPRIL; FENOFIBRATE; FLUOCINOLONE ACETONIDE; LOSARTAN; RANIBIZUMAB; SIMVASTATIN; VASCULOTROPIN ANTIBODY;

ARTICLE; BLINDNESS; BLOOD PRESSURE REGULATION; CATARACT; CONGENITAL BLOOD VESSEL MALFORMATION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DYSLIPIDEMIA; GLAUCOMA; GLYCEMIC CONTROL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; LOW LEVEL LASER THERAPY; MICROANEURYSM; NON INSULIN DEPENDENT DIABETES MELLITUS; OFF LABEL DRUG USE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD VESSEL; RETINA CAPILLARY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINAL CAPILLARY CLOSURE; RETINAL THICKNESS; SCREENING TEST; VASCULAR DISEASE; VASCULAR TORTUOSITY; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE; CANADA; PRACTICE GUIDELINE;

CANADA; DIABETIC RETINOPATHY; HUMANS;

EID: 84876015645     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.038     Document Type: Article

References (66)

1. Kempen J.H., O'Colmain B.J., Leske M.C., et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004, 122:552-563.
2. Klein R., Klein B.E., Moss S.E. Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992, 15:1875-1891.
3. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984, 91:1464-1474.
4. Kaur H., Maberley D., Chang A., Hay D. The current status of diabetes care, diabetic retinopathy screening and eye-care in British Columbia's First Nations Communities. Int J Circumpolar Health 2004, 63:277-285.
5. Maberley D., Walker H., Koushik A., Cruess A. Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis. CMAJ 2003, 168:160-164.
6. Vu H.T., Keeffe J.E., McCarty C.A., Taylor H.R. Impact of unilateral and bilateral vision loss on quality of life. Br J Ophthalmol 2005, 89:360-363.
7. Cusick M., Meleth A.D., Agron E., et al. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care 2005, 28:617-625.
8. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985, 103:1796-1806.
9. Ferris F.L. How effective are treatments for diabetic retinopathy?. JAMA 1993, 269:1290-1291.
10. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978, 85:82-106.
11. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996, 94:505-537.
12. Younis N., Broadbent D.M., Harding S.P., Vora J.P. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabet Med 2003, 20:758-765.
13. Younis N., Broadbent D.M., Vora J.P., et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003, 361:195-200.
14. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989, 107:237-243.
15. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989, 107:244-249.
16. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984, 102:520-526.
17. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984, 102:527-532.
18. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VII. Diabetic nonproliferative retinal lesions. Ophthalmology 1987, 94:1389-1400.
19. Klein R., Moss S.E., Klein B.E., et al. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989, 96:1501-1510.
20. Kohner E.M., Aldington S.J., Stratton I.M., et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998, 116:297-303.
21. Kohner E.M., Stratton I.M., Aldington S.J., et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001, 18:178-184. UKPDS Group.
22. Maguire A., Chan A., Cusumano J., et al. The case for biennial retinopathy screening in children and adolescents. Diabetes Care 2005, 28:509-513.
23. Klein R. Screening interval for retinopathy in type 2 diabetes. Lancet 2003, 361:190-191.
24. Whited J.D. Accuracy and reliability of teleophthalmology for diagnosing diabetic retinopathy and macular edema: a review of the literature. Diabetes Technol Ther 2006, 8:102-111.
25. Klein R., Klein B.E., Moss S.E., Cruickshanks K.J. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998, 105:1801-1815.
26. Davis M.D., Fisher M.R., Gangnon R.E., et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998, 39:233-252.
27. Klein B.E., Moss S.E., Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990, 13:34-40.
28. Chew E.Y., Klein M.L., Ferris F.L., et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996, 114:1079-1084.
29. Qiao Q., Keinanen-Kiukaanniemi S., Laara E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol 1997, 50:153-158.
30. Diabetes C. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000, 23:1084-1091. Complications Trial Research Group.
31. Chew E.Y., Mills J.L., Metzger B.E., et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995, 18:631-637.
32. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
33. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
34. Mohamed Q., Gillies M.C., Wong T.Y. Management of diabetic retinopathy: a systematic review. JAMA 2007, 298:902-916.
35. White N.H., Sun W., Cleary P.A., et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008, 126:1707-1715.
36. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
37. Group A.S., Group A.E.S., Chew E.Y., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244.
38. Beulens J.W., Patel A., Vingerling J.R., et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009, 52:2027-2036.
39. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998, 116:874-886.
40. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
41. Mauer M., Zinman B., Gardiner R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51.
42. Chaturvedi N., Porta M., Klein R., et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008, 372:1394-1402.
43. Sjolie A.K., Klein R., Porta M., et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008, 372:1385-1393.
44. Miljanovic B., Glynn R.J., Nathan D.M., et al. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004, 53:2883-2892.
45. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
46. Keech A.C., Mitchell P., Summanen P.A., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697.
47. Bergerhoff K., Clar C., Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol Metab Clin North Am 2002, 31:779-793.
48. Aiello L.P., Cahill M.T., Wong J.S. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001, 132:760-776.
49. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology 1991, 98(5 Suppl):757-765.
50. Chew E.Y., Ferris F.L., Csaky K.G., et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003, 110:1683-1689.
51. Nguyen Q.D., Brown D.M., Marcus D.M., et al. Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE. Ophthalmology 2012, 119:789-801.
52. Mitchell P., Bandello F., Schmidt-Erfurth U., et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011, 118:615-625.
53. Elman M.J., Bressler N.M., Qin H., et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011, 118:609-614.
54. Rajendram R., Fraser-Bell S., Kaines A., et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema. Arch Ophthalmol 2012, 130:972-979.
55. Pearson P.A., Comstock T.L., Ip M., et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011, 118:1580-1587.
56. Campochiaro P.A., Brown D.M., Pearson A., et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011, 118:626-635.
57. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990, 108:958-964.
58. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial-Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988, 95:1307-1320.
59. Smiddy W.E., Flynn H.W. Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol 1999, 43:491-507.
60. El-Asrar A.M., Al-Mezaine H.S., Ola M.S. Changing paradigms in the treatment of diabetic retinopathy. Curr Opin Ophthalmol 2009, 20:532-538.
61. Chew E.Y., Klein M.L., Murphy R.P., et al. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol 1995, 113:52-55.
62. Chew E.Y., Benson W.E., Remaley N.A., et al. Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25. Arch Ophthalmol 1999, 117:1600-1606.
63. Brown J.S., Mahmoud T.H. Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy. Retina 2011, 31:1983-1987.
64. Fonda G.E. Optical treatment of residual vision in diabetic retinopathy. Ophthalmology 1994, 101:84-88.
65. Bernbaum M., Albert S.G. Referring patients with diabetes and vision loss for rehabilitation: who is responsible?. Diabetes Care 1996, 19:175-177.
66. Buxton M.J., Sculpher M.J., Ferguson B.A., et al. Screening for treatable diabetic retinopathy: a comparison of different methods. Diabet Med 1991, 8:371-377.